PMC:7100515 / 28289-29045 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T238","span":{"begin":91,"end":96},"obj":"Body_part"},{"id":"T239","span":{"begin":476,"end":484},"obj":"Body_part"},{"id":"T240","span":{"begin":516,"end":521},"obj":"Body_part"},{"id":"T241","span":{"begin":523,"end":528},"obj":"Body_part"},{"id":"T242","span":{"begin":622,"end":627},"obj":"Body_part"}],"attributes":[{"id":"A238","pred":"fma_id","subj":"T238","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A239","pred":"fma_id","subj":"T239","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A240","pred":"fma_id","subj":"T240","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A241","pred":"fma_id","subj":"T241","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A242","pred":"fma_id","subj":"T242","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"Table 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T8","span":{"begin":91,"end":96},"obj":"Body_part"},{"id":"T9","span":{"begin":622,"end":627},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Table 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T269","span":{"begin":51,"end":59},"obj":"Disease"},{"id":"T270","span":{"begin":64,"end":72},"obj":"Disease"},{"id":"T271","span":{"begin":97,"end":105},"obj":"Disease"},{"id":"T272","span":{"begin":121,"end":129},"obj":"Disease"},{"id":"T273","span":{"begin":147,"end":155},"obj":"Disease"},{"id":"T274","span":{"begin":171,"end":179},"obj":"Disease"},{"id":"T275","span":{"begin":208,"end":216},"obj":"Disease"},{"id":"T276","span":{"begin":244,"end":252},"obj":"Disease"},{"id":"T277","span":{"begin":281,"end":289},"obj":"Disease"},{"id":"T278","span":{"begin":318,"end":326},"obj":"Disease"},{"id":"T279","span":{"begin":355,"end":363},"obj":"Disease"},{"id":"T280","span":{"begin":368,"end":376},"obj":"Disease"}],"attributes":[{"id":"A269","pred":"mondo_id","subj":"T269","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A270","pred":"mondo_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A271","pred":"mondo_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A272","pred":"mondo_id","subj":"T272","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A273","pred":"mondo_id","subj":"T273","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A274","pred":"mondo_id","subj":"T274","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A275","pred":"mondo_id","subj":"T275","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A276","pred":"mondo_id","subj":"T276","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A277","pred":"mondo_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A278","pred":"mondo_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A279","pred":"mondo_id","subj":"T279","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A280","pred":"mondo_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Table 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T634","span":{"begin":23,"end":33},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T635","span":{"begin":470,"end":475},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T636","span":{"begin":506,"end":509},"obj":"http://purl.obolibrary.org/obo/CLO_0001230"},{"id":"T637","span":{"begin":506,"end":509},"obj":"http://purl.obolibrary.org/obo/CLO_0037237"},{"id":"T638","span":{"begin":506,"end":509},"obj":"http://purl.obolibrary.org/obo/CLO_0050903"},{"id":"T639","span":{"begin":506,"end":509},"obj":"http://purl.obolibrary.org/obo/CLO_0054249"},{"id":"T640","span":{"begin":506,"end":509},"obj":"http://purl.obolibrary.org/obo/CLO_0054250"},{"id":"T641","span":{"begin":506,"end":509},"obj":"http://purl.obolibrary.org/obo/CLO_0054251"},{"id":"T642","span":{"begin":506,"end":509},"obj":"http://purl.obolibrary.org/obo/CLO_0054252"},{"id":"T643","span":{"begin":516,"end":521},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T644","span":{"begin":523,"end":528},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T645","span":{"begin":737,"end":738},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Table 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T217","span":{"begin":485,"end":492},"obj":"Chemical"}],"attributes":[{"id":"A217","pred":"chebi_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/CHEBI_60004"}],"text":"Table 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

    LitCovid-PD-GO-BP

    {"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T52","span":{"begin":567,"end":579},"obj":"http://purl.obolibrary.org/obo/GO_0009293"},{"id":"T53","span":{"begin":650,"end":662},"obj":"http://purl.obolibrary.org/obo/GO_0009293"}],"text":"Table 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T204","span":{"begin":0,"end":82},"obj":"Sentence"},{"id":"T205","span":{"begin":83,"end":146},"obj":"Sentence"},{"id":"T206","span":{"begin":147,"end":170},"obj":"Sentence"},{"id":"T207","span":{"begin":171,"end":207},"obj":"Sentence"},{"id":"T208","span":{"begin":208,"end":243},"obj":"Sentence"},{"id":"T209","span":{"begin":244,"end":280},"obj":"Sentence"},{"id":"T210","span":{"begin":281,"end":317},"obj":"Sentence"},{"id":"T211","span":{"begin":318,"end":354},"obj":"Sentence"},{"id":"T212","span":{"begin":355,"end":522},"obj":"Sentence"},{"id":"T213","span":{"begin":523,"end":593},"obj":"Sentence"},{"id":"T214","span":{"begin":594,"end":708},"obj":"Sentence"},{"id":"T215","span":{"begin":709,"end":756},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"1144","span":{"begin":132,"end":133},"obj":"Gene"},{"id":"1145","span":{"begin":121,"end":131},"obj":"Species"},{"id":"1146","span":{"begin":147,"end":155},"obj":"Species"},{"id":"1147","span":{"begin":156,"end":163},"obj":"Species"},{"id":"1148","span":{"begin":180,"end":187},"obj":"Species"},{"id":"1149","span":{"begin":217,"end":224},"obj":"Species"},{"id":"1150","span":{"begin":253,"end":260},"obj":"Species"},{"id":"1151","span":{"begin":290,"end":297},"obj":"Species"},{"id":"1152","span":{"begin":327,"end":334},"obj":"Species"},{"id":"1153","span":{"begin":83,"end":90},"obj":"Species"},{"id":"1154","span":{"begin":97,"end":105},"obj":"Species"},{"id":"1155","span":{"begin":171,"end":179},"obj":"Disease"},{"id":"1156","span":{"begin":208,"end":216},"obj":"Disease"},{"id":"1157","span":{"begin":244,"end":252},"obj":"Disease"},{"id":"1158","span":{"begin":281,"end":289},"obj":"Disease"},{"id":"1159","span":{"begin":318,"end":326},"obj":"Disease"},{"id":"1163","span":{"begin":51,"end":59},"obj":"Species"},{"id":"1164","span":{"begin":73,"end":81},"obj":"Species"},{"id":"1165","span":{"begin":64,"end":72},"obj":"Disease"},{"id":"1171","span":{"begin":510,"end":515},"obj":"Gene"},{"id":"1172","span":{"begin":379,"end":380},"obj":"Gene"},{"id":"1173","span":{"begin":355,"end":363},"obj":"Species"},{"id":"1174","span":{"begin":368,"end":378},"obj":"Species"},{"id":"1175","span":{"begin":436,"end":443},"obj":"Species"}],"attributes":[{"id":"A1144","pred":"tao:has_database_id","subj":"1144","obj":"Gene:43740568"},{"id":"A1145","pred":"tao:has_database_id","subj":"1145","obj":"Tax:2697049"},{"id":"A1146","pred":"tao:has_database_id","subj":"1146","obj":"Tax:694009"},{"id":"A1147","pred":"tao:has_database_id","subj":"1147","obj":"Tax:9606"},{"id":"A1148","pred":"tao:has_database_id","subj":"1148","obj":"Tax:9606"},{"id":"A1149","pred":"tao:has_database_id","subj":"1149","obj":"Tax:9606"},{"id":"A1150","pred":"tao:has_database_id","subj":"1150","obj":"Tax:9606"},{"id":"A1151","pred":"tao:has_database_id","subj":"1151","obj":"Tax:9606"},{"id":"A1152","pred":"tao:has_database_id","subj":"1152","obj":"Tax:9606"},{"id":"A1153","pred":"tao:has_database_id","subj":"1153","obj":"Tax:9606"},{"id":"A1154","pred":"tao:has_database_id","subj":"1154","obj":"Tax:694009"},{"id":"A1155","pred":"tao:has_database_id","subj":"1155","obj":"MESH:C000657245"},{"id":"A1156","pred":"tao:has_database_id","subj":"1156","obj":"MESH:C000657245"},{"id":"A1157","pred":"tao:has_database_id","subj":"1157","obj":"MESH:C000657245"},{"id":"A1158","pred":"tao:has_database_id","subj":"1158","obj":"MESH:C000657245"},{"id":"A1159","pred":"tao:has_database_id","subj":"1159","obj":"MESH:C000657245"},{"id":"A1163","pred":"tao:has_database_id","subj":"1163","obj":"Tax:694009"},{"id":"A1164","pred":"tao:has_database_id","subj":"1164","obj":"Tax:9606"},{"id":"A1165","pred":"tao:has_database_id","subj":"1165","obj":"MESH:C000657245"},{"id":"A1171","pred":"tao:has_database_id","subj":"1171","obj":"Gene:59272"},{"id":"A1172","pred":"tao:has_database_id","subj":"1172","obj":"Gene:43740568"},{"id":"A1173","pred":"tao:has_database_id","subj":"1173","obj":"Tax:694009"},{"id":"A1174","pred":"tao:has_database_id","subj":"1174","obj":"Tax:2697049"},{"id":"A1175","pred":"tao:has_database_id","subj":"1175","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}